Biotechnology Innovation Organization’s Post

Ophthopedia Update:Intra-Anterior Chamber Injection of Ranibizumab in Advanced Pediatric Vitreoretinal Diseases: This case series evaluates the use of intra-anterior chamber injection of anti–vascular endothelial growth factor in the treatment of pediatric vitreoretinal diseases. #Ophthalmology #Eyecare #JAMA

#Rarediseases affect some of the most vulnerable patients in healthcare: children. In part 3 of our blog series on FDA designation, we’re highlighting the rare pediatric disease designation (RPDD). Read all about it: https://bit.ly/3wcZBD7 #RareDiseaseDesignations #RPDD #PediatricRareDisease

Although Clostridioides difficile infection (C.diff or CDI) is less common in children than in adults, it also has a slightly different risk profile among pediatric patients that’s worth noting. “CDI in pediatric patients is strongly associated with predisposing factors and medical conditions, including antibiotic use, malignancy, inflammatory bowel disease and immune suppression,” says Thomas Sferra, MD, Division Chief of Pediatric Gastroenterology at UH Rainbow Babies & Children’s Hospital and the Martin and Betty Rosskamm Endowed Chair in Pediatric Gastroenterology. “In hospitalized children, CDI risk is highest in those patients with malignancy. Because of this, therapies to prevent recurrence of CDI in pediatric patients are needed. It’s a clinical challenge worth confronting," Dr. Sferra says. “Children are resilient, as we know, but CDI can lead to a severe illness and complicate an existing one,” he says. “It also can be an issue if it becomes recurrent. Once you have two infections with C. difficile, it's much more common to have three. Many patients struggle to clear this infection.” To address this issue and advance the standard of care, Dr. Sferra and UH Rainbow have played a key role in the clinical trial and recent FDA approval of the agent bezlotoxumab (Zinplava) for use in children with CDI. The monoclonal antibody, given in conjunction with antibiotics, had previously just been approved for adults as a preventive measure against the condition. To read more, please visit https://lnkd.in/gxByhbuZ #healthykids #physicianexcellence #patientsfirst

https://lnkd.in/dRNTjF66 FIRST REAL LIFE EVIDENCE OF NIRSEVIMAB EFFECTIVENESS! CLOSE TO 80%!!! These results point towards a high effectiveness of nirsevimab in preventing severe RSV bronchiolitis in infants requiring PICU admission from 75.9% (48.5–88.7) to 80.6% (61.6–90.3) depending on the assumptions. These real-world estimates are in line with the efficacy observed in clinical studies: the efficacy of nirsevimab was evaluated in clinical trials against very severe medically attended RSV lower respiratory tract disease between 64.2% (−12.1–88.6) and 87.5% (62.9–95.8) depending on gestational age [6, 11] and at 75.7% (32.8–92.9) in a pragmatic trial. This strong effectiveness is also consistent with a Spanish study looking at RSV-related hospitalizations and French surveillance data showing a reduced impact of the 2023–2024 bronchiolitis epidemic on hospitalizations of infants under 3 months compared to previous years and in contrast to older infants. xavier saez-llorens Enrique Chacon-Cruz

Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review Neurological manifestations have been widely reported in adults with COVID-19, yet the extent of involvement among the pediatric population is currently poorly characterized. The objective of our systematic review is to evaluate the association of SARS-CoV-2 infection with neurological symptoms and neuroimaging manifestations in the pediatric population. A literature search of Cochrane Library; EBSCO CINAHL; Global Index Medicus; OVID AMED, Embase, Medline, PsychINFO; and Scopus was conducted in accordance with the Peer Review of Electronic Search Strategies form (October 1, 2019 to March 15, 2022). Studies were included if they reported (1) COVID-19-associated neurological symptoms and neuroimaging manifestations in individuals aged <18 years with a confirmed, first SARS-CoV-2 infection and were (2) peer-reviewed. Full-text reviews of 222 retrieved articles were performed, along with subsequent reference searches.

📢 Check out this peer-reviewed article, co-authored by a BRAC JPGSPH researcher, titled "Risk Factors and Clinical Prognosis Associated With RSV-ALRI Intensive Care Unit Admission in Children <2 Years of Age: A Multicenter Study", published in The Pediatric Infectious Disease Journal. 👉 Click to read: https://lnkd.in/gQacTt2Y

Coverage gaps in empiric antibiotic regimens used to treat serious bacterial infections in neonates and children in Southeast Asia and the Pacific. This study reports coverage provided by aminopenicillins in neonatal sepsis/meningitis to be 26%, whilst gentamicin coverage was 45%. Third-generation cephalosporin coverage was only 29% in neonatal sepsis/meningitis, 51% in paediatric sepsis and 65% in paediatric meningitis. Carbapenems were estimated to provide the highest coverage: 81% in neonatal sepsis/meningitis, 83% in paediatric sepsis and 79% in paediatric meningitis. Alarmingly high rates of resistance to commonly prescribed empirical therapies for neonatal and paediatric sepsis and meningitis in the Asia–Pacific region. https://lnkd.in/exhbcurR

There is a strong growth in pediatric obesity services ahead, plus new ways to prevent pediatric respiratory syncytial virus (RSV). These are a few articles from the latest Vizient Pediatric Tech Watch.

There is a strong growth in pediatric obesity services ahead, plus new ways to prevent pediatric respiratory syncytial virus (RSV). These are a few articles from the latest Vizient Pediatric Tech Watch.

There is a strong growth in pediatric obesity services ahead, plus new ways to prevent pediatric respiratory syncytial virus (RSV). These are a few articles from the latest Vizient Pediatric Tech Watch.